-- Scott Roberts
MONDAY, Feb. 28 (HealthDay News) -- Edarbi (azilsartan
medoxomil) has been approved by the U.S. Food and Drug
Administration to treat adults with high blood pressure
Clinical trials showed Edarbi was more effective in lowering
high blood pressure over 24 hours than two previously FDA-approved
drugs, Diovan (valsartan) and Benicar (olmesartan), the agency said
in a news release.
Edarbi helps lower blood pressure by blocking the action of the
hormone angiotensin II, the FDA said. The most common adverse
reaction was diarrhea, maker Takeda Pharmaceutical North America
said in a statement.
Edarbi has a boxed label warning that it shouldn't be used by
women who are pregnant. If a woman becomes pregnant while taking
the drug, it should be discontinued as soon as possible, the FDA
Takeda is based in Deerfield, Ill.
The U.S. National Heart Lung and Blood Institute has more about
high blood pressure.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.